Preventive Blood Tests When Stroke Runs in Your Family

Start With a Focused Preventive Blood Test Plan

Ask which relative was affected, whether the event was ischaemic or haemorrhagic, and the age at onset. A first-degree relative with ischaemic stroke before 55 years in men or 65 years in women is the history that most often changes my starting threshold for testing and prevention.

Kantesti AI is an AI blood test analyzer that places lipid, glucose and kidney values beside the family pattern rather than treating each flag as a diagnosis. In my experience, this prevents the common mistake of pursuing 25 low-yield markers while an LDL-C of 178 mg/dL sits unaddressed.

Blood tests do not directly predict every stroke; atrial fibrillation, blood pressure, sleep apnoea, smoking and carotid disease are often more decisive than any laboratory value. Use a biomarker reference guide to record exact units, laboratory ranges and medicines before a clinical appointment.

The Core Lipid Panel That Should Not Be Missed

For most adults, nonfasting lipid testing is acceptable; a fasting repeat is sensible when triglycerides exceed 400 mg/dL because calculated LDL-C becomes unreliable. Non-HDL-C equals total cholesterol minus HDL-C and captures cholesterol in all potentially atherogenic particles.

The 2018 AHA/ACC cholesterol guideline identifies LDL-C of 190 mg/dL or higher as severe primary hypercholesterolaemia, a level that warrants treatment discussion without waiting for a risk calculator (Grundy et al., 2019). LDL-C between 70 and 189 mg/dL still matters when Lp(a), diabetes, kidney disease or early family stroke coexist.

I have reviewed panels in lean, active patients whose total cholesterol looked merely borderline but whose non-HDL-C was 175 mg/dL and triglycerides were 210 mg/dL. That pattern is often more actionable than the reassuring HDL number; our guide to lipid panels and profiles explains why.

Why One-Time Lp(a) Screening Belongs in the Roadmap

Do not convert mg/dL to nmol/L using a fixed multiplier: apo(a) size differs between people, so the relationship is assay-dependent. The 2022 European Atherosclerosis Society consensus recommends measuring Lp(a) at least once in every adult, with cascade testing in families affected by high Lp(a) or premature cardiovascular disease (Kronenberg et al., 2022).

Kantesti AI is an AI blood test interpretation platform that identifies whether the laboratory reported mass units or particle units before comparing Lp(a) with the appropriate threshold. This small technical point avoids an alarming but incorrect interpretation in roughly the patients whose report does not state the assay format clearly.

A high Lp(a) is not something you caused by eating eggs or missing a supplement, and no validated diet reliably lowers it by 50%. The practical response is tighter attention to modifiable risk—particularly LDL-C, blood pressure and smoking—and a conversation about screening relatives; see our detailed Lp(a) testing guide.

Add ApoB When Cholesterol Numbers Look Confusing

Each LDL, remnant and Lp(a) particle carries one ApoB molecule, so ApoB functions as a particle count rather than a measure of cholesterol cargo. Discordance matters: an LDL-C of 112 mg/dL with ApoB of 122 mg/dL can indicate more arterial particle exposure than LDL-C alone suggests.

ApoB is most informative when triglycerides are 200 mg/dL or higher, in type 2 diabetes, metabolic syndrome, or known high Lp(a). It is not mandatory for every annual panel, and a non-HDL-C result often provides a useful lower-cost alternative if ApoB is unavailable.

In clinic, I use the triglyceride-to-HDL pattern as a prompt to look harder, not as a diagnosis of insulin resistance. Patients can compare these markers with our explanation of high ApoB risk clues before deciding with their clinician whether a repeat fasting panel adds value.

Check Glucose Exposure Before It Causes Silent Vascular Damage

HbA1c reflects approximately 8 to 12 weeks of glycaemia, but it can read falsely high or low with haemoglobin variants, anaemia, recent blood loss, kidney failure or altered red-cell survival. A fasting plasma glucose of 100 to 125 mg/dL is prediabetes, while 126 mg/dL or higher requires confirmation in an asymptomatic person.

A normal fasting glucose does not always rule out early dysglycaemia; I see this in people with triglycerides of 240 mg/dL and fasting glucose of 92 mg/dL whose HbA1c is already 6.0%. Conversely, one HbA1c of 5.8% after iron-deficiency anaemia should be interpreted cautiously rather than treated as a verdict.

Kantesti AI checks glucose and HbA1c against the complete metabolic context, including red-cell indices that can distort the result. For a practical retest framework, read how to improve HbA1c over 90 days.

Include Kidney Function and Urine Albumin in Stroke Prevention

Creatinine alone is a blunt tool because muscular people may have higher baseline values and older adults may have deceptively normal creatinine despite reduced filtration. eGFR uses creatinine with age and sex, while cystatin C can help settle borderline results when the clinical decision is consequential.

Urine albumin-to-creatinine ratio is not a blood test, but leaving it out of a family-stroke assessment misses early vascular injury. ACR of 30 to 300 mg/g is moderately increased albuminuria; values above 300 mg/g require more urgent renal and cardiovascular evaluation.

Kantesti AI flags an eGFR trend rather than reacting to a single decimal point, because hydration, exercise and laboratory variation can move creatinine by 10% or more. Our overview of eGFR and albuminuria stages explains what should be repeated and when.

Do Not Let Blood Tests Distract From Blood Pressure

Measure twice in the morning and twice in the evening for at least 4 days, ideally 7, using a validated upper-arm monitor and a correctly sized cuff. The first day is commonly discarded because people tend to sit awkwardly or feel understandably tense.

Blood tests become targeted when pressure is severe, resistant or accompanied by low potassium. Potassium below 3.5 mmol/L with hypertension can prompt evaluation for primary aldosteronism, but normal potassium does not exclude it.

A 42-year-old with LDL-C of 96 mg/dL and average home pressure of 148/92 mmHg has a more urgent prevention issue than a peer with modestly higher cholesterol and pressure of 116/72 mmHg. Our secondary hypertension lab guide outlines when renin, aldosterone and kidney testing are genuinely useful.

Recognise the Lab Clues of Familial Hypercholesterolaemia

Familial hypercholesterolaemia is usually inherited in an autosomal dominant pattern, so each child of an affected person has about a 50% chance of inheriting the variant. LDL-C may be lower than 190 mg/dL after treatment, during illness, or in some genetic forms, which is why untreated historical values matter.

Look for relatives with bypass surgery, stents, heart attack or stroke before age 55 in men or 65 in women—not simply anyone prescribed a statin after retirement. Tendon xanthomas are specific when present but absent in many genetically affected people, so their absence should not reassure you.

Dr. Thomas Klein often asks patients to photograph or request old results because the pre-treatment LDL-C is diagnostically more useful than the value after five years of medication. A deeper explanation of genetic LDL elevation can make that family conversation less abstract.

When Clotting and Homocysteine Tests Actually Help

Factor V Leiden and prothrombin variants are linked more clearly to venous thromboembolism than to typical arterial stroke. Testing someone with no clot history after a parent’s stroke at 78 often creates ambiguous findings without changing blood-pressure or lipid management.

Fasting homocysteine above about 15 µmol/L is elevated, but mild elevations can reflect reduced kidney function, B12 or folate deficiency, smoking, hypothyroidism and several medicines. Lowering homocysteine with vitamins has not consistently prevented vascular events in well-nourished populations; the exception is treating a proven nutritional deficiency or rare homocystinuria.

Testing during acute illness, pregnancy, while using anticoagulants or soon after a clot can distort protein C, protein S and antithrombin results. If a clinician does order a panel, our coagulation test guide covers preparation pitfalls that change interpretation.

Use hs-CRP as Context, Not as a Stroke Crystal Ball

An hs-CRP result above 10 mg/L should usually be repeated after the person is well, because a dental infection, influenza, hard training session or inflammatory flare can swamp the subtle vascular signal. For this reason, I do not order hs-CRP during a cold and then build a lifelong prevention plan around it.

The 2021 ESC prevention guideline treats persistently elevated inflammatory markers as one consideration among many, not a substitute for LDL-C, diabetes and pressure assessment (Visseren et al., 2021). In a patient with LDL-C of 165 mg/dL, high hs-CRP strengthens the prevention conversation; in isolation, it is nonspecific.

Kantesti AI applies clinical validation rules that distinguish a likely acute-phase result from a stable prevention marker, while our medical validation standards describe why an isolated red flag should never be treated as a diagnosis. A useful companion is our explanation of the CRP-to-albumin pattern.

Low-Value Tests to Skip Unless the Story Changes

D-dimer rises with age, infection, pregnancy, surgery and many ordinary inflammatory states, so it is designed to help assess suspected acute clotting rather than future stroke risk. Ordering it in a well person with no symptoms frequently leads to repeat imaging and anxiety rather than useful prevention.

MTHFR testing is not recommended to evaluate thrombosis risk because common variants do not reliably alter management. Likewise, an isolated oxidised LDL result does not supersede LDL-C, ApoB, non-HDL-C or Lp(a), each of which has clearer treatment implications.

A broad screen can generate 5% out-of-range results by chance even in healthy people when 100 analytes are ordered. For age-appropriate restraint, compare this roadmap with our family wellness testing plan, then reserve specialist testing for a specific clinical question.

When to Test and How Often to Repeat Results

Recheck a lipid panel about 4 to 12 weeks after starting or changing lipid-lowering therapy, then every 3 to 12 months as clinically appropriate. HbA1c needs roughly 3 months to show the full effect of a glucose intervention because it reflects red-cell exposure over time.

Avoid comparing triglycerides after a 14-hour fast with a previous nonfasting sample after a large meal, or creatinine after a marathon with a rested baseline. A reliable trend requires similar timing, medication status, hydration and laboratory method whenever possible.

Kantesti AI is an AI-powered blood test analysis tool that compares longitudinal values rather than declaring a 3 mg/dL LDL-C shift meaningful on its own. Our practical guide on blood-test frequency by risk offers a reasonable schedule to take to your clinician.

Turn One Family Result Into Sensible Cascade Screening

If one person has Lp(a) of 160 nmol/L, parents, siblings and children should consider one Lp(a) measurement because levels are largely genetically set. The same logic applies to an untreated LDL-C above 190 mg/dL, although a clinician may recommend formal genetic counselling in selected families.

Write down the relative’s age at stroke, subtype if known, smoking status, diabetes, blood pressure treatment and lipid values. A family story that includes embolic stroke from atrial fibrillation should not be interpreted in exactly the same way as repeated early carotid or coronary disease.

Privacy matters here: relatives can share a short risk summary without circulating a complete laboratory report or app login. Our family history tracker suggests the handful of details that make another family member’s medical visit more productive.

What to Do With Results—and When It Is Urgent

Bring a one-page list of your blood pressure average, smoking or nicotine exposure, medicines, pregnancy plans, migraines with aura, diabetes history and family ages at stroke. This information changes prevention decisions more than an isolated vitamin level, particularly when LDL-C exceeds 160 mg/dL or Lp(a) exceeds 125 nmol/L.

Dr. Thomas Klein’s practical rule is simple: address the result that has an evidence-based action before chasing the one that merely looks unusual. That might mean confirming an HbA1c of 6.6%, evaluating LDL-C of 205 mg/dL, or treating sustained home pressure of 142/88 mmHg—not ordering another 30 tests.

Kantesti AI can organise uploaded results into questions for your appointment, but it does not replace emergency assessment, prescribing or a clinician who knows your examination and history. Our physicians on the Medical Advisory Board support a cautious, evidence-led approach to interpretation.

Frequently Asked Questions